secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-059392
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC reports Q3 2023 net loss; cash $256.2M; ORIC-114 CNS responses
-------------------------------------------------------------------

- Cash, cash equivalents and investments $256.2M as of Sept 30, 2023; expected to fund operations into late 2025.
- R&D expenses $22.4M in Q3 2023, up from $14.7M in Q3 2022 due to pipeline advancement.
- ORIC-114 Phase 1b data at ESMO showed CNS complete response in EGFR exon 20 NSCLC patient; favorable safety.
- Initial ORIC-533 data in multiple myeloma to be presented at ASH December 2023.
- ORIC-944 initial Phase 1b data in prostate cancer expected Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017023059392/0000950170-23-059392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017023059392/oric-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer